期刊文献+

GATA-4基因增加骨髓间充质干细胞抗缺氧能力的探讨

Discussion of GATA-4 improving MSCs hypoxia resistance
原文传递
导出
摘要 目的探讨GATA-4基因对骨髓间充质干细胞(MSCs)在低氧环境下存活能力的影响。方法将GATA-4基因转染大鼠MSCs,以转染空质粒的MSCs做对照,通过蛋白印迹法检测GATA-4转染效果。模拟体内心肌梗死氧化应激损伤,在低氧环境下培养48 h,观察MSCs形态变化。通过MTT细胞增殖测定、膜联蛋白V-PE凋亡检测和乳酸脱氢酶(LDH)释放评价MSCs存活能力。结果在低氧环境下,GATA-4基因修饰组与转染空质粒的对照组相比,MTT摄取增加、膜联蛋白V阳性细胞数降低、LDH释放减少,差异有统计学意义(P<0.05)。结论转录因子GATA-4可以增加MSCs抗缺氧能力,增加细胞存活;为MSCs移植治疗缺血性心肌病、增加细胞存活提供新的方法。 Objective To elucidate the effects of GATA-4 on MSCs survival ability in hypoxic condition. Methods Rat MSCs were transfected with GATA-4 gene, and MSCs transfected with blank plasmid were regarded as contrast. The GATA-4 transfection effect was detected by Western blotting. The MSCs were cultured after exposure to hypoxia for 48h to imitate the myocardial infarction oxidative stress injury in vivo. The morphology of MSCs was observed. The rate of MTT cell proliferation, the positive rate of annexin V-PE apoptosis detection and the level of LDH were tested to evaluate the MSCs survival ability. Results The positive rate of annexin V-PE apoptosis and the level of LDH signifi- cantly decreased and the rate of MTT cell proliferation increased in GATA-4 transduced MSCs(MSCGATA-4) than in the control group(MSCNUH). The difference was statistically significant(P 〈0.05). Conclusion GATA-4 promotes MSCs hypoxia resistance and survival ability, which provides a new pathway to treat ischemic cardiomyopathy by MSCs transplantation and increase cell survival ability.
出处 《山东大学学报(医学版)》 CAS 北大核心 2013年第7期6-9,共4页 Journal of Shandong University:Health Sciences
关键词 GATA-4 骨髓间充质干细胞 低氧环境 MSCS移植 缺血性心肌病 GATA-4 MSCs Hypoxic condition MSCs transplantation Ischemic cardiomyopathy
  • 相关文献

参考文献16

  • 1Gnecchi M,Danieli P,Cervio E. Mesenchymal stem celltherapy for heart disease [ J ]. Vascular Pharmacology,2012,57(1) :48-55.
  • 2张兆华,王一彪,栾云,苏宏,马宇,林梅,孙若鹏.骨髓间充质干细胞移植治疗实验性大鼠肺动脉高压损伤的作用[J].山东大学学报(医学版),2011,49(8):31-34. 被引量:4
  • 3Ramesh B, Bishi D K,Rallapalli S, et al. Ischemic car-diac tissue conditioned media induced differentiation ofhuman mesenchymal stem cells into early stage cardio-myocytes[ J]. Cytotechnology, 2012,64(5):563-575.
  • 4Robey T E, Saiget M K, Reinecke H, et al. Systems ap-proaches to preventing transplanted cell death in cardiacrepair[J]. J Mol Cell Cardiol, 2008,45(4) :567-581.
  • 5Li W,Ma N, Ong L L, et al. Bcl-2 engineered MSCs in-hibited apoptosis and improved heart function [ J ]. StemCells,2007,25(8):2118-2127.
  • 6Mangi A A, Noiseux N, Kong D,et al. Mesenchymalstem cells modified with Akt prevent remodeling and re-store performance of infarcted hearts [ J ]. Nat Med,2003,9(9) :1195-2201.
  • 7Pasha Z, Wang Y,Sheikh R, et al. Preconditioning en-hances cell survival and differentiation of stem cells duringtransplantation in infarcted myocardium [ J]. CardiovascRes, 2008, 77( 1) : 134-142.
  • 8Kobayashi S, Volden P, Timm D, et al. Transcriptionfactor GATA4 inhibits doxorubicin- induced autophagyand cardiomyocyte death[ J]. J Biol Chem, 2010, 285(1):793-804.
  • 9Aries A, Paradis P, Lefebvre C,et al. Essential role ofGATA4 in cell survival and drug- induced cardiotoxicity[J]. Proc Natl Acad Sci USA, 2004,101 (18):6975-6980.
  • 10Gruh I,Beilner J, Blomer U,et al. No evidence oftransdifferentiation of human endothelial progenitor cellsinto cardiomyocytes after coculture with neonatalrat car-diomyocytes [ J ]. Circulation,2006, 113 (10) : 1326-1334.

二级参考文献35

  • 1Morrell N W, Adnot S, Archer S L, et al. Cellular and molecular basis of pulmonary arterial hypertension [ J ]. J Am Coll Cardiol, 2009, 54( I Suppl) :S20-S31.
  • 2Patel K M, Crisostomo P, Lahm T, et al. Mesenchymal stem cells attenuate hypoxic pulmonary vasoconstriction by a paracrine mechanism[ J ]. Journal of Surgical Research, 2007, 143 (2) :281-285.
  • 3Harada-Shiba M, Takamisawa I, Miyata K, et al. Intratracheal gene transfer of adrenomedullin using polyplex nanomicelles attenuates rnonocrotaline-induced pulmonary hypertension in rats[J]. Mol Ther, 2009, 17 (7) : 1180- 1186.
  • 4Kanki-Horimoto S, Horimoto H, Mieno S, et al. Implantation of mesenchymal stem ceils overexpressing endothelial nitric oxide synthase improves right ventricular impair ments caused by pulmonary hypertension [ J ]. Circulation, 2006, 114( 1 Suppl) :181-185.
  • 5Takemiya K, Kai H, Yasukawa H, et al. Mesenchymal stem cell-based prostacyclin synthase gene therapy for pulmonary hypertension rats [J]. Basic Res Cardiol, 2010, 105 ( 3 ) :409-417.
  • 6Cohen E D, Ihida-Stansbury K, Lu M M, et al. Wnt signaling regulates smooth muscle precursor development in the mouse lung via a tenascin C/PDGFR pathway [J]. J Clin Invest, 2009, 119(9) :2538-2549.
  • 7Pittenger M F, Martin B J. Mesenchyma stern cells and their potential as cardiac therapeutics[J].Circulation Research, 2004, 95:9-20.
  • 8Wollert K C, Drexler H. Mesenchymal stem cells for myocardial infarction: Promises and pitfalls[J].Circulation, 2005, 112 : 151-153.
  • 9Chang L T, Sun C K, Sheu J J, et al. Cilostazol therapy attenuates monomonocrotaline-induced pulmonary arterial hypertension in rat model [J]. Circ, 2008, 72(5) :825-831.
  • 10Badillo A T, Redden R A, Zhang L. Treatment of diabetic wounds with fetal murine mesenchymal stromal cells enhance wound closure [ J ]. Cell Tissue Res, 2007, 329(2) :301-311.

共引文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部